
## **Gilad Yahalom**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1067662/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Identification of an early-stage Parkinson's disease neuromarker using event-related potentials, brain network analytics and machine-learning. PLoS ONE, 2022, 17, e0261947.	2.5	12
2	Botulinum Injections for Idiopathic Cervical Dystonia: a Longitudinal Study. Neurotoxicity Research, 2021, 39, 1352-1359.	2.7	7
3	Expert opinion on diagnosing, treating and managing patients with cerebrotendinous xanthomatosis (CTX): a modified Delphi study. Orphanet Journal of Rare Diseases, 2021, 16, 353.	2.7	13
4	Psychiatric Patients on Neuroleptics: Evaluation of Parkinsonism and Quantified Assessment of Gait. Clinical Neuropharmacology, 2020, 43, 1-6.	0.7	8
5	Visual self-motion cues are impaired yet overweighted during visual–vestibular integration in Parkinson's disease. Brain Communications, 2020, 2, fcaa035.	3.3	31
6	A case of probable Parkinson's disease after SARS-CoV-2 infection. Lancet Neurology, The, 2020, 19, 804-805.	10.2	158
7	Age at Onset of Parkinson's Disease Among Ashkenazi Jewish Patients: Contribution of Environmental Factors, LRRK2 p.G2019S and GBA p.N370S Mutations. Journal of Parkinson's Disease, 2020, 10, 1123-1132.	2.8	21
8	Opsoclonus-myoclonus as a presentation of post-malaria neurological syndrome. Journal of Travel Medicine, 2020, 27, .	3.0	2
9	Analysis of common and rare <i>VPS13C</i> variants in late-onset Parkinson disease. Neurology: Genetics, 2020, 6, 385.	1.9	19
10	The Contribution of Evaluating Daily Functioning to Identify Initial Signs of Mild Cognitive Impairment (MCI) in Parkinson's Disease (PD). American Journal of Occupational Therapy, 2020, 74, 7411500035p1-7411500035p1.	0.3	0
11	Smartphone Based Timed Up and Go Test Can Identify Postural Instability in Parkinson's Disease. Israel Medical Association Journal, 2020, 22, 37-42.	0.1	9
12	Increased yield of full GBA sequencing in Ashkenazi Jews with Parkinson's disease. European Journal of Medical Genetics, 2019, 62, 65-69.	1.3	49
13	Decreasing battery life in subthalamic deep brain stimulation for Parkinson's disease with repeated replacements: Just a matter of energy delivered?. Brain Stimulation, 2019, 12, 845-850.	1.6	16
14	Catastrophizing mediates the relationship between non-motor symptoms and quality of life in Parkinson's disease. Disability and Health Journal, 2019, 12, 673-678.	2.8	11
15	Carriers of both GBA and LRRK2 mutations, compared to carriers of either, in Parkinson's disease: Risk estimates and genotype-phenotype correlations. Parkinsonism and Related Disorders, 2019, 62, 179-184.	2.2	58
16	Three-Dimensional Orofacial Changes Occurring After Proportional Condylectomy in Patients With Condylar Hyperplasia Type 1B (Unilateral Hemimandibular Elongation). Journal of Oral and Maxillofacial Surgery, 2019, 77, 803-817.	1.2	11
17	Repetitive Deep TMS for Parkinson Disease: A 3-Month Double-Blind, Randomized Sham-Controlled Study. Journal of Clinical Neurophysiology, 2018, 35, 159-165.	1.7	32
18	The impact of early versus late levodopa administration. Journal of Neural Transmission, 2017, 124, 471-476.	2.8	5

GILAD YAHALOM

#	Article	IF	CITATIONS
19	Repetitive deep transcranial magnetic stimulation for motor symptoms in Parkinson's disease: A feasibility study. Clinical Neurology and Neurosurgery, 2016, 140, 73-78.	1.4	14
20	Costeff syndrome: clinical features and natural history. Journal of Neurology, 2014, 261, 2275-2282.	3.6	26
21	Cardiac stress test is normal in preâ€motor Parkinson's disease. Movement Disorders, 2014, 29, 1158-1162.	3.9	1
22	Estimated glomerular filtration rate in a population with normal to mildly reduced renal function as predictor of cardiovascular disease. European Journal of Preventive Cardiology, 2014, 21, 941-948.	1.8	16
23	Correlates of quality of sexual life in male and female patients with Parkinson disease and their partners. Parkinsonism and Related Disorders, 2014, 20, 1085-1088.	2.2	38
24	Motor progression of Parkinson's disease with the leucineâ€rich repeat kinase 2 G2019S mutation. Movement Disorders, 2014, 29, 1057-1060.	3.9	27
25	Neurological Outcome in Cerebrotendinous Xanthomatosis Treated With Chenodeoxycholic Acid. Clinical Neuropharmacology, 2013, 36, 78-83.	0.7	102
26	Chronic Kidney Disease and Clinical Outcome in Patients With Acute Stroke. Stroke, 2009, 40, 1296-1303.	2.0	218